MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the  H.C.

CARDAMYST™ (etripamil) nasal spray launch for PSVT is  gaining traction; breadth of unique prescribers supports potential future adoption Express Scripts national formulary coverage secured as company makes progress toward broad patient access Atrial Fibrillation-RVR Phase 3 registration trial

MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the first quarter

Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium MONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone ®   Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and

MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone ®   Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will present at the  25 th Annual

MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 123,000 options (the “Options”) to purchase the Company’s common shares,

Decision Expands Coverage to National Preferred Formulary Commercially Insured Lives MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone ®   Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVT Participants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placebo CARDAMYST launch

MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone ®   Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated poster presentation titled

Conference Call and Webcast Scheduled for Friday, March 20 at 8:30am ET MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on